Liver Mass Domingo, Elizabeth Guzman, Alexander Joseph Hipolito, April Lorraine.

16
Liver Mass Domingo, Elizabeth Guzman, Alexander Joseph Hipolito, April Lorraine

Transcript of Liver Mass Domingo, Elizabeth Guzman, Alexander Joseph Hipolito, April Lorraine.

Page 1: Liver Mass Domingo, Elizabeth Guzman, Alexander Joseph Hipolito, April Lorraine.

Liver Mass

Domingo, Elizabeth

Guzman, Alexander Joseph

Hipolito, April Lorraine

Page 2: Liver Mass Domingo, Elizabeth Guzman, Alexander Joseph Hipolito, April Lorraine.

Case 1b

General Data: – 35 year old, male– Nonsmoker, non-alcoholic– elevated AFP (400 ng/ml) on routine tests– Asymptomatic– No history of Hepa B infection– No history of blood transfusion– PE is essentially unremarkable

Page 3: Liver Mass Domingo, Elizabeth Guzman, Alexander Joseph Hipolito, April Lorraine.

Differential Diagnosis For elevated AFP: 400ng/ml (N= < 10ng/ml) Also consider laboratory error and ask for repeat A

FP level determination

1. Hepatoma

- primary malignant tumor of the liver

- may present w/ hepatosplenomegaly, pain, hypoglycemia, weight loss or anorexia, ascites, portal hypertension, jaundice

2. Hepatocellular Carcinoma

- has elevated AFP in 60-75% of the cases, commonly presents w/ enlarged liver on palpation, with sufficient irregularity or nodularity to permit differentiation from cirrhosis

Page 4: Liver Mass Domingo, Elizabeth Guzman, Alexander Joseph Hipolito, April Lorraine.

Differential Diagnosis

3. Alcoholic Cirrhosis

- may be clinically silent and in many cases(10-40%) are discovered incidentally at laparotomy or autopsy

4. Testicular tumor

- malignant teratoma, embryonal cancer, yolk sac tumor.

- unlikely in our case, px is already 35 y/o

5. Chronic hapatitis

- unlikely in our case, no hx of hepatitis infection nor blood transfusions

Page 5: Liver Mass Domingo, Elizabeth Guzman, Alexander Joseph Hipolito, April Lorraine.

Probable Diagnosis Fibrolamellar Hepatocellular

Carcinoma- a distinctive clinical and pathologic subtype of hepatocellular carcinoma (HCC)- occurs in young adults (20-40 y/o) without underlying parenchymal liver disease- alpha-fetoprotein level are usually not elavated- non-encapsulated but well circumscribed and contains fibrous lamellae- slowly growing tumor

Page 6: Liver Mass Domingo, Elizabeth Guzman, Alexander Joseph Hipolito, April Lorraine.

AFP levels

1° Liver CA

Malignant teratomas

Hepatitis and cirrhosis

CA of pancreas/stomach/biliary tract

Page 7: Liver Mass Domingo, Elizabeth Guzman, Alexander Joseph Hipolito, April Lorraine.

Diagnostic Evaluation

Abdominal CT scan is the preferred test for the detection, diagnosis, staging, and postoperative follow-up of HCC

MRI is useful in detecting & characterizing primary tumors. It is more sensitive in detecting multiple intrahepatic recurrent lesions but less sensitive in detecting extrahepatic disease.

Page 8: Liver Mass Domingo, Elizabeth Guzman, Alexander Joseph Hipolito, April Lorraine.

Ultrasound can be used intra-operatively as well as monitoring the progression of known intrahepatic lesions.

Radionucleotide sulfur-colloid scans are ocassionally useful in the differentiation of fibrolamellar carcinoma from other tumors.

Percutaneous biopsy with ultrasound guidance may be necessary for a definitive pre-operative diagnosis of fibrolamellar HCC.

Page 9: Liver Mass Domingo, Elizabeth Guzman, Alexander Joseph Hipolito, April Lorraine.

Lab Studies AFP levels may be elevated since this p

rotein is commonly produced by HCC. However, this is not a sensitive parameter since AFP levels may be normal in more than one-third of the patients.

Normal adult levels of AFP are below 10 ng/mL

Page 10: Liver Mass Domingo, Elizabeth Guzman, Alexander Joseph Hipolito, April Lorraine.

Follow-up Fibrolamellar carcinoma is an aggressive tum

or that progresses to recurrent liver masses and metastatic lymph node metastases in most patients.

Recurrent lesions often develop 6-18 months after attempted curative resection and may progress rapidly; therefore, follow-up imaging is recommended at 2- to 4-month intervals for at least 12-18 months after resection of the primary tumor.

The early detection of metastatic disease is important because surgical resection of metastases improves patient survival rates.

Page 11: Liver Mass Domingo, Elizabeth Guzman, Alexander Joseph Hipolito, April Lorraine.

Management

Medical Care Surgical Care

Page 12: Liver Mass Domingo, Elizabeth Guzman, Alexander Joseph Hipolito, April Lorraine.

Medical Care Patt et al reported a phase II clinical trial of sy

stemic, continuous 5-fluorouracil and thrice-weekly subcutaneous recombinant interferon alfa-2b for liver cancers.

demonstrated that this regimen was an effective treatment for patients with FLC, suggesting that neoadjuvant chemoimmunotherapy may play a previously unappreciated role in treatment of FLC

Page 13: Liver Mass Domingo, Elizabeth Guzman, Alexander Joseph Hipolito, April Lorraine.

Surgical Care

Hepatic Resection Liver Transplantation

Page 14: Liver Mass Domingo, Elizabeth Guzman, Alexander Joseph Hipolito, April Lorraine.

Hepatic Resection problems:

– presents of advanced-stage disease – direct invasion of adjacent organs– lymphadenopathy– limited metastais– presence of extensive liver involvement

contraindication:– involvement of the main portal vein or hep

atic artery

Page 15: Liver Mass Domingo, Elizabeth Guzman, Alexander Joseph Hipolito, April Lorraine.

Liver Transplantation problems:

– limited donor availability with attendant waiting lists

– high cost– sustained morbidity

contraindications:– presence of extrahepatic disease– comorbid factors– presence of vascular invasion– poorly differentiated histologic grade

Page 16: Liver Mass Domingo, Elizabeth Guzman, Alexander Joseph Hipolito, April Lorraine.

Prognosis

48% resectability rate 32 months average survival time 63% 5-year survival time prognosis better than usual type of hepa

tocellular carcinoma